Le Lézard
Classified in: Health
Subject: SVY

Histology and Cytology Market size is expected to reach USD 26.9 billion by 2025


NEW YORK, June 19, 2017 /PRNewswire/ -- Highlights

·         The global histology and cytology market size is expected to reach USD 26.9 billion by 2025, according to a new report by Grand View Research, Inc.

·         Globally, the increasing incidence of cancer and growing adoption of cytological tests due to its less invasive nature as compared to biopsy & higher reliability are likely to drive the market during the forecast period.

·         Cytology was the largest segment in the histology and cytology market in 2016 and is expected to maintain its dominance during the forecast period due to the recent entry of various tests for cytological testing and advantages over histology such as faster analysis and economical technique.

·         Cytology is further segmented into cervical, breast, and other cancers based on its application.

The global histology and cytology market size is expected to reach USD 26.9 billion by 2025, according to a new report by Grand View Research, Inc. Globally, the increasing incidence of cancer and growing adoption of cytological tests due to its less invasive nature as compared to biopsy & higher reliability are likely to drive the market during the forecast period.

Furthermore, rising well-equipped clinical laboratories in developing countries and favorable reimbursement for cancer screening and laboratory tests are likely to positively affect the market growth. Advancements in the cytology and histology save the time for pathologists, hence this makes the service more cost-effective.

Cytology was the largest segment in the histology and cytology market in 2016 and is expected to maintain its dominance during the forecast period due to the recent entry of various tests for cytological testing and advantages over histology such as faster analysis and economical technique.

Cytology is further segmented into cervical, breast, and other cancers based on its application. Cervical cancer segment dominated in 2016 due to higher incidence and growing demand of test for the cervical cancer screening. Furthermore, breast cancer was considered as the second largest segment due to rising awareness about breast cancer screening in emerging countries.

Further Key Findings From the Report Suggest:
? Rising incidence of cancer and growing investment by players are expected to propel growth at the fastest rate with a CAGR of 13.5% from 2017 to 2025
? Cytology testing segment dominated in 2016 and is estimated to account for majority of the share by 2025.
? Cytological testing for cervix is the largest contributing segment of the market. This can be attributed to high incidence and more adoption of the test for cervix screening.
? The U.S. market was the largest in 2016 and is expected to maintain its dominance during forecast period due to higher awareness about screening and higher healthcare expenditure as compared to the developing countries.
? In February 2014, Roche launched a new test for cervical cancer screening, Automated CINtec PLUS cytology test, which improves the detection of cervical precancer.
? The industry in Asia Pacific is projected to witness substantial growth over the next decade owing to growing investment by several clinics in the region, growing healthcare expenditure, and increasing adoption of screening tests.
? Some of the key players operating are Abbott Laboratories; Becton, Dickinson and Company; F. Hoffmann-La Roche Ltd.; Hologic, Inc.; Life Technologies Corporation; Sysmex Corporation; Thermo Fisher Scientific, Inc.; and Trivitron Healthcare.
Read the full report: http://www.reportlinker.com/p04946472/Histology-and-Cytology-Market-Analysis-By-Type-of-Examination-Cytology-Cervical-Cancer-Breast-Cancer-Others-Histology-By-Region-North-America-Europe-Asia-Pacific-And-Segment-Forecasts.html

About Reportlinker
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

http://www.reportlinker.com


__________________________
Contact Clare: [email protected]
US: (339)-368-6001
Intl: +1 339-368-6001

SOURCE Reportlinker


These press releases may also interest you

at 01:24
Sedana Medical AB (publ) announces that all 235 randomized patients have been recruited for its INSPiRE-ICU 1 phase III clinical trial in the United States. Concurrently, the identical INSPiRE-ICU 2 trial is nearing completion, with 23 of 235...

at 01:17
Quarter 1, 2024 - High profitability and strong cash flow Net sales decreased 4.1% to SEK 34,850m (36,352)Organic growth amounted to -4.0%, of which volume accounted for -1.8% and price/mix -2.2%. Excluding restructuring and exited contracts, volumes...

at 00:05
ImmunityBio, Inc. , an immunotherapy company, today announced positive overall survival results in the QUILT 3.055 study of 2nd- and 3rd-line NSCLC patients who progressed after checkpoint inhibitor therapy (pembrolizumab, nivolumab, or atezolizumab)...

at 00:05
The Insurance Institute for Highway Safety is updating its vehicle-to-vehicle front crash prevention test to address crashes that occur at higher speeds and those in which the struck vehicle is a motorcycle or large truck. Only one of the first 10...

at 00:00
Nutriessential.com recently announced its expansion into Oceania, Asia, and the Gulf. The company has been providing science-backed GMP-certified supplements in the US, Europe and Canada since 2005 and decided to expand owing to rising global demands...

24 avr 2024
Summit Clinical Research LLC ("Summit") is deeply saddened by the death of Co-Founder and Chairman Dr. Stephen Harrison. Summit mourns Dr. Harrison and extends its heartfelt condolences to his family and loved ones.   During an illustrious 30-year...



News published on and distributed by: